Login
$NVCR
$11.30 -$0.53 (4.48%) Live

$NVCR 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Regulation FD Disclosure

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

29 Oct 2026 8-K: Results of Operations and Financial Condition

Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide

01 Oct 2026 8-K: Regulation FD Disclosure

Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advance...

09 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

(b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Mr. Scannell's reti...

01 Sep 2026 8-K: Other Events

In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecu...

23 Jul 2026 8-K: Results of Operations and Financial Condition

Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications

30 Jun 2026 8-K: Regulation FD Disclosure

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel

18 Jun 2026 8-K: Regulation FD Disclosure

Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma

05 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of this NovoCure Limited Amended and Restated 2024 Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its shareholders by enabling the Company to offer Eligible Employees, Consu...

30 Apr 2026 8-K: Results of Operations and Financial Condition

Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio®

09 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On behalf of Novocure GmbH, we would like to thank you for your willingness to assume the role of Chief Medical Officer while concurrently performing your responsibilities as Chief Innovation Officer. Your readiness to take on this expan...

26 Mar 2026 8-K: Regulation FD Disclosure

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

26 Feb 2026 8-K: Results of Operations and Financial Condition

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

24 Feb 2026 8-K: Regulation FD Disclosure

On February 2, 2026, the registrant's U.S. subsidiary, Novocure Inc. (the "Company") received a letter dated January 29, 2026 from the Centers for Medicare & Medicaid Services ("CMS") that the Company's billing privileges for its product...

11 Feb 2026 8-K: Regulation FD Disclosure

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer

05 Feb 2026 8-K: Regulation FD Disclosure

On January 30, 2026, the registrant's U.S. subsidiary, Novocure Inc. (the "Company") received a letter dated January 29, 2026 from the Centers for Medicare & Medicaid Services ("CMS") that the Company's billing privileges for its product...

12 Jan 2026 8-K: Results of Operations and Financial Condition

Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million

01 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

THIS SEPARATION AND RELEASE AGREEMENT (“Agreement”) made November 24, 2025 (the “Effective Date”), between Novocure GmbH (including its successors and assigns, the “Company”), and Ashley Cordova (the “Executive”).

30 Oct 2025 8-K: Results of Operations and Financial Condition

Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025

15 Sep 2025 8-K: Regulation FD Disclosure

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support